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ALSPACBackground:Cross-sectional studies have reported elevated concentrations of inflammatorymarkers in psychosis
and depression. However, questions regarding temporality and specificity of association, crucial for understand-
ing the potential role of inflammation, remain.
Methods: Based on 2224 ALSPAC birth cohort participants, we used regression analyses to test associations of
interleukin-6 (IL-6) and C-reactive protein (CRP) levels at age 9 with risks for psychosis (psychotic experiences;
negative symptoms; psychotic disorder), and depression (depressive episode; symptom score) at age 24. Regres-
sionmodels were adjusted for sex, ethnicity, social class and bodymass index.We tested for linearity (using qua-
dratic terms) and specificity (using bi-variate probit regression) of association, and used multiple imputation to
explore the impact of missing data.
Results: After adjustments, higher IL-6 levels at age 9 were associated with increased risk of psychotic disorder
(OR = 1.56; 95% C.I., 1.09–2.21 per SD increase in IL-6; OR=2.60; 95% C.I., 1.04-6.53 for the top compared
with bottom third of IL-6) and depressive episode (OR = 1.14; 95% C.I., 0.99–1.32 per SD increase in IL-6;
OR=1.49; 95% C.I., 1.02–2.18 for the top comparedwith bottom third of IL-6). IL-6was associatedwith negative
symptoms after adjusting for depression (β = 0.09; 95% C.I., 0.01–0.22). There was no evidence for outcome-
specific associations of IL-6. Childhood CRP was not associated with adult psychosis or depression.
Conclusions: Evidence for similar, longitudinal, dose-response associations suggest that elevated childhood IL-6
could be a shared risk factor for adult psychosis and depression. The IL-6 pathway may represent a novel target
for treatment and prevention of these disorders.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There is mounting evidence for an immune/inflammatory compo-
nent to psychosis and depression (Brown and Derkits, 2010; Karlsson
and Dalman, 2020; Khandaker et al., 2015). Meta-analyses of cross-
sectional studies have reported increased levels of circulating inflam-
matory markers in depression (Goldsmith et al., 2016; Haapakoski
et al., 2015; Howren et al., 2009; Köhler et al., 2017; Osimo et al.,y Research Group, Department
ith Building, Robinson Way,
.V. This is an open access article und2019) and psychosis (Fernandes et al., 2016; Karageorgiou et al., 2019;
Miller et al., 2011; Potvin et al., 2008; Upthegrove et al., 2014) compared
with controls, indicating a potentially transdiagnostic role of inflamma-
tion inmajormental disorders. However, cross-sectional studies cannot
address whether inflammation is a cause or consequence of illness
(i.e., reverse causality). Emerging evidence from longitudinal studies,
which are better suited to examine direction of association, suggest as-
sociations between elevated levels of circulating inflammatory markers
at baseline and increased risks for depression and psychosis at follow-
up. A previous study from the Avon Longitudinal Study of Parents and
Children (ALSPAC) birth cohort reported that higher levels of interleu-
kin (IL-6), a proinflammatory cytokine, at age 9 were associated with
risks for depression and psychosis at age 18 years (Khandaker et al.,er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ulation samples (Gimeno et al., 2009; Kappelmann et al., 2019; Lamers
et al., 2019; Metcalf et al., 2017; Wium-Andersen et al., 2013; Zalli
et al., 2016). While these longitudinal studies go some way to address
the issue of direction of association, there are three key outstanding
questions regarding the potential role of childhood inflammatory
markers in depression and psychosis.
First, most longitudinal studies have typically focused on a single
outcome, so cannot test specificity; i.e., whether the association of child-
hood inflammationwith psychosis and depression at follow-up is stron-
ger for one outcome than other, indicating specificity of effect, or is
similar between outcomes. Addressing this issue is important since it
may elucidate potential unique or common mechanisms for psychosis
and depression. Second, previous studies of childhood inflammatory
markers and psychotic outcomes at follow-up have typically focused
on positive symptoms. Negative symptoms are key components of the
psychosis syndrome and phenomenologically similar to depressive
symptoms, but it remains unclear whether childhood inflammation is
associated with negative symptoms after controlling for current mood.
Third, while previous studies have reported associations of childhood
inflammatory markers with depressive and psychotic symptoms in
adolescence/early-adulthood (Khandaker et al., 2014; Zalli et al.,
2016), it remains unclear whether these associations persist into adult-
hood. This is important because it could extend the temporal association
to early adulthood, a period when most cases of psychiatric disorders
are likely to emerge.
We used data from the ALSPAC birth cohort to examine temporality
and specificity of association of IL-6 and CRP levels at age 9 and risks for
psychosis and depression at age 24, addressing some of the key gaps in
the literature. As outcomes, for psychosis we used psychotic experi-
ences (PEs), negative symptoms, and psychotic disorder. For depres-
sion, we used depressive episode and depression severity score. We
examined linearity of association, and whether inflammation was a
shared or specific risk factor for psychosis and depression. Finally, we
conducted sensitivity analyses to assess the robustness of findings.
First, we examinedwhether associationswere stronger inmoderate/se-
vere depressive episode compared with mild depressive episode. Sec-
ond, we repeated our main analyses after imputing missing data.
We hypothesised that childhood inflammatory markers would be
associated with risks for psychotic and depression outcomes at follow-
up, suggestive of a potential role of childhood inflammation in patho-
genesis of adult depression and psychosis.
2. Material and methods
2.1. Description of cohort and sample selection
The ALSPAC birth cohort initially recruited 14,541 pregnant women
resident in a geographically defined region in southwest England, with
expected dates of delivery between 1.4.1991 and 31.12.1992, resulting
in 14,062 live births (Boyd et al., 2013; Fraser et al., 2013; Northstone
et al., 2019). An additional 913 participants were recruited
subsequently. See www.bris.ac.uk/alspac/researchers/data-access/
data-dictionary/ for a fully searchable data dictionary. Study data were
collected and managed using REDCap electronic data capture tools
hosted at University of Bristol (Harris et al., 2019; Harris et al., 2009).
Ethical approval for the study was obtained from the ALSPAC Ethics
and Law Committee and Local Research Ethics Committees. All partici-
pants provided informed consent.
The risk set for the current study comprised 5081 participants with
data for IL-6 and CRP at age 9. Of these, up to 2224 participants had
data on psychosis outcomes, and 2219 participants had data on depres-
sion outcomes at age 24 (See Supplementary Fig. 1 for available sam-
ples). We excluded participants with CRP levels >10 mg/L to
minimize potential confounding by current infection/ chronic inflam-
matory illness.702.2. Psychotic outcomes at age 24
2.2.1. Psychotic experiences (PEs)
PEs were identified through the face-to-face, semi-structured
Psychosis-Like Symptom Interview (PLIKSi) conducted by trained psy-
chology graduates and were coded according to the definitions in the
Schedules for Clinical Assessment in Neuropsychiatry, Version 2.0. The
PLIKSi had good interrater reliability (Intraclass correlation: 0.81; 95%
CI, 0.68–0.89) and test-retest reliability (0.9; 95% CI 0.83–0.95)
(Sullivan et al., 2020). PEs, occurring in the last six months, covering
the three main domains of positive psychotic symptoms were elicited:
hallucinations (visual and auditory), delusions (spied on, persecuted,
thoughts read, reference, control, grandiosity, and other), and thought
interference (insertion, withdrawal, and broadcasting). After
cross-questioning, interviewers rated PEs as not present, suspected, or
definitely present. Our primary outcome was cases of definite PEs; the
comparator group was suspected/ no PEs, to maximize the specificity
of the outcome variable.
2.2.2. Psychotic disorder
Cases of psychotic disorder were defined (Sullivan et al., 2020) as
having interviewer-rated definite PEs that were not attributable to the
effects of sleep/fever, had occurred regularly at least once per month
over the previous 6 months, and were either (i) very distressing, (ii)
negatively impacted social/occupational functioning, or (iii) led to
help-seeking from a professional source. In addition, we included par-
ticipants meeting the criteria for Comprehensive Assessment of At-
Risk Mental State (CAARMS) (Yung et al., 2005) psychotic disorder
(threshold psychotic symptoms present for >1 week).
2.2.3. Negative psychotic symptoms
Negative symptoms were assessed at age 24 using a question-
naire featuring ten questions based on items from the Community
Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002).
Questions covered difficulties with interest, motivation, emotional
reactivity, pleasure, and sociability. Participants rated each item
on a 4-point scale (0 = never; 1 = sometimes; 2 = often; and
3 = always). We were interested in symptoms that were more fre-
quent, thus potentially clinically relevant. Therefore, we recoded
each item into a binary variable by coding ‘always’ and ‘often’ as
1 = symptom present; ‘never’ and ‘sometimes’ as 0 = symptom
absent. A total score was constructed by summing ten items
(range 0–10).
2.3. Depression outcomes at age 24 years
Depression was measured using the computerised version of
the Clinical Interview Schedule–Revised (CIS-R), a widely used
standardised self-administered tool for measuring depression and
anxiety in community samples (Lewis et al., 1992). The CIS-R as-
sesses symptoms of depression occurring in the past week and pro-
vides a diagnosis of depressive episode (mild, moderate or severe)
based on the International Statistical Classification of Diseases, 10th
Revision (ICD-10) criteria, which was used as the primary outcome
(ICD-10 codes F32.0/F32.1/F32.2). The CIS-R also provides a total de-
pression severity score (0−21) comprising scores for depressed
mood, depressive thoughts, fatigue, concentration, and sleep prob-
lems, which we also used as an outcome.
2.4. Measurement of IL-6 and CRP at age 9 years
Blood samples were collected from non-fasting participants dur-
ing clinic assessment. Samples were immediately spun, frozen and
stored at −80 °C. There was no evidence of freeze-thaw cycles dur-
ing storage. In 2008, IL-6 was measured by ELISA (R&D systems,
Abingdon, UK), and high-sensitivity CRP (hsCRP) was measured by
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UK, Welwyn Garden City, UK). All assay coefficients of variation
were <5%. Data on IL-6 and CRP were available for 5071 and 5081
participants, respectively. In the total sample, CRP values ranged
from 0.01 to 45.17 mg/L. Thirty-two subjects had CRP levels
>10 mg/L and were excluded from analysis.
2.5. Assessment of potential confounders
We adjusted for sex (binary), ethnicity (White vs other), social class
(defined from father's occupation, coded categorically as per the UK Of-
fice of National Statistics classification system: I, II, III non-manual, III
manual, IV, V), and body mass index (BMI) (weight (kg)/height (m2))
measured at age 9.
2.6. Statistical analysis
Pearson's Correlation was used to test correlations between IL-6
and CRP levels, which were log-transformed and standardised (Z-
transformed). We compared the prevalence of binary psychiatric
outcomes at age 24 across tertiles of IL-6/CRP at age 9 using likeli-
hood ratio tests.
2.6.1. Association between childhood inflammatory markers and adult
psychiatric outcomes
We examined the associations of IL-6/CRP with binary psychiatric
outcomes (PEs, psychotic disorder, depressive episode) using logistic
regression, and with continuous outcomes (depression severity score,
negative symptom score) using linear regression. Continuous outcomes
were log-transformed and standardised (Z-transformed). Inflammatory
markers were coded as both continuous and categorical variables
(tertiles). Using tertiles, odds ratios (ORs) were calculated for partici-
pants in the top and middle thirds compared with the bottom third of
IL-6/CRP distributions. Linearity of association was tested by inspection
of the ORs over the thirds of the inflammatory marker distribution. For
logistic regression analyses, ORs and 95% confidence intervals (CIs) rep-
resent the increase in risk of outcome per standard deviation (SD) in-
crease in exposure. Linear regression beta coefficients and 95% CIs
represent the increase in outcome (in SD) per SD increase in exposure.
All regression models were adjusted for sex, ethnicity, social class and
BMI. Furthermore, regression models for depression severity score
were adjusted for negative symptom score and vice versa. Non-
linearity was examined by including a quadratic term in regression
models (IL-6/CRP-squared).
2.6.2. Specificity of associations for IL-6 and CRP with psychotic and
depressive outcomes
We used bivariate probit regression to test for commonality or
specificity of the associations of IL-6/CRP with psychotic and depres-
sive outcomes. Probit regression jointly modelled the outcomes of
definite PEs/psychotic disorder and depressive episode in relation
to IL-6/CRP, and then tested for equality of regression parameters
expressing the effect of IL-6/CRP on each outcome using likelihood
ratio tests. We compared a model that allowed estimates to differ
between outcomes with a model where the exposure effect was
constrained to be the same for both outcomes. We converted probit
estimates into ORs by multiplying probit parameters by 1.6
(Ntzoufras et al., 2003).
2.6.3. Sensitivity analyses using moderate/severe depressive episode as
outcome
Weusedmultinomial logistic regression to calculate ORs and 95% CIs
for the association of childhood inflammatory markers (continuous)
with mild vs moderate/severe depressive episode, compared to no de-
pressive episode. A likelihood ratio test was used to compare the effect
estimates.712.6.4. Sensitivity analyses using multiple imputation of missing data
We used multiple imputation using chained equations (MICE)
(Buuren and Groothuis-Oudshoorn, 2011) to impute missing data for
covariates using the MICE package in R (Buuren and Groothuis-
Oudshoorn, 2011). MICE is a flexible and practical approach to handling
missing data, produces asymptotically unbiased estimates and standard
errors, and is asymptotically efficient (White et al., 2011). See Supple-
mentary Data for further information. From 100 imputed datasets, we
used linear and logistic regression to examine the associations of IL-6
and CRP at age 9 and psychiatric outcomes at age 24, as above. Analyses
were performed individually on all imputed datasets, with estimates
pooled using Rubin's rules (Rubin, 1987).
3. Results
3.1. Baseline characteristics of sample
Of the 2224 participants with data on childhood inflammatory
markers and psychotic outcomes at age 24, 163 met criteria for definite
PEs (7.3%) and 30 for psychotic disorder (1.3%). Of the 2219 participants
with data on exposures and depression outcomes at age 24, 214 met
ICD-10 criteria for depressive episode (9.6%). See Supplementary
Table 1 for baseline characteristics of the sample. IL-6 and CRP levels
at age 9 were moderately correlated (r = 0.45, p < 0.001).
3.2. Prevalence of psychosis and depression at age 24 per tertile of IL-6/CRP
at age 9
The prevalence of all psychiatric outcomes was higher for partici-
pants in the top third of IL-6 at age 9 years compared with those in
the bottom third (p-values of χ2 tests <0.05). A similar trend was ob-
served for CRP (Fig. 1).
3.3. Longitudinal associations of IL-6 and CRP at age 9 with psychotic out-
comes at age 24
Increasing levels of IL-6 (continuous variable) were associated with
higher risk of psychotic disorder (adjusted OR = 1.56; 95% C.I.,
1.09–2.21; p = 0.014) (Table 1), consistent with a linear dose-
response effect (p-value for quadratic term = 0.638) (Supplementary
Table 2). Using IL-6 as a categorical variable, participants in the top,
compared with bottom, third of IL-6 at baseline had higher risk of psy-
chotic disorder at follow-up (adjusted OR = 2.60; 95% C.I., 1.04–6.53;
p = 0.031) (Table 2).
IL-6 levels (continuous variable) at age 9 were associated with in-
creased negative symptoms at age 24 after controlling for potential con-
founders including current mood (adjusted β = 0.09; 95% C.I.,
0.01–0.22; p = 0.041) (Table 3), consistent with a linear effect (p-
value for quadratic term = 0.597) (Supplementary Table 3). Similarly,
participants in the top, compared with bottom, third of IL-6 at age 9
had higher negative symptoms (adjusted β = 0.20; 95% C.I.,
0.04–0.31; p = 0.021) (Supplementary Table 5).
There was no evidence for an association of IL-6 with PEs (Table 1),
or of CRP with any psychotic outcomes (Tables 1 and 3; Supplementary
Tables 4 and 6).
3.4. Longitudinal associations of IL-6 and CRP at age 9 with depression at
age 24
Participants in the top, compared with bottom, third of IL-6 at age 9
had higher risk of depressive episode at age 24 (adjusted OR = 1.49;
95% C.I., 1.02–2.18; p = 0.035) (Table 2). Similarly, participants in the
top, compared with bottom third of IL-6 at baseline had higher depres-
sion severity score at follow-up (adjusted β=0.43; 95% C.I., 0.01–1.15;
p = 0.049) (Supplementary Table 4). Using IL-6 as a continuous vari-
able, there was weak evidence for an association of IL-6 levels with
Fig. 1. Psychiatric outcomes at age 24 per tertile of IL-6 and CRP levels at age 9.
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(Table 1), consistentwith a linear dose response effect (p-value for qua-
dratic term = 0.327). However, there was no evidence for anTable 1
Odds ratios for psychosis and depression (binary outcomes) at age 24 per SD increase i
Outcome Risk factor OR (95% C.I.)
Unadjusted Ad
Definite PEs IL-6 1.12 (0.95–1.31) 1.0
CRP 1.08 (0.93–1.27) 1.0
Psychotic disorder IL-6 1.42 (1.06–2.01) 1.5
CRP 0.95 (0.65–1.37) 1.0
Depressive episode IL-6 1.17 (1.02–1.34) 1.1
CRP 1.10 (0.96–1.26) 1.0
Table 2
Odds ratios for psychosis and depression (binary outcomes) at age 24 for participants in
Outcome (binary variable) Risk factor (vs bottom tertile) OR (95% C.I.)
Unadjusted
Definite PEs Bottom tertile 1 [Reference]
Middle tertile 0.83 (0.54–1.26)
Top tertile 1.34 (0.92–1.96)
Psychotic disorder Bottom tertile 1 [Reference]
Middle tertile 0.59 (0.20–1.76)
Top tertile 1.96 (1.01–4.61)
Depressive episode Bottom tertile 1 [Reference]
Middle tertile 1.25 (0.87–1.81)
Top tertile 1.65 (1.16–2.34)
Table 3
Increase in Negative and Depressive Symptoms (SDs) at age 24 per SD increase in IL-6
Outcome Risk factor Beta coefficient (95% C.I.)
Unadjusted
Negative symptoms IL-6 0.07 (−0.03, 0.16)
CRP −0.01 (−0.10, 0.09)
Depressive symptoms score IL-6 0.13 (−0.12, 0.39)
CRP 0.14 (−0.13, 0.41)
72association of IL-6 (continuous variable) with depression severity
score at age 24 (Table 3), or of CRP with any depressive outcomes
(Tables 1 and 3).n IL-6 and CRP levels at age 9.
p-value for adjusted model







top and middle tertiles of IL-6 distribution compared with bottom tertile at age 9.
p-value for adjusted model










and CRP Levels at Age 9.
p-value for adjusted model
Adjusted for sex, ethnicity, social class, BMI
0.09 (0.00, 0.19) 0.041
0.04 (−0.07, 0.15) 0.446
0.03 (−0.25, 0.29) 0.897
−0.04 (−0.34, 0.27) 0.441
Table 4
Commonality of associations for IL-6 and CRP at age 9 with psychotic disorder and depressive episode at age 24.
Risk factor Odds ratio (95% C.I.) LRTa comparing specific vs. common effect
Specific effect on psychotic disorder Specific effect on depressive episode Common effect on both outcomes χ2-statistic, p-valueb
IL-6 1.29 (1.01–1.65) 1.13 (1.01–1.28) 1.16 (1.04–1.30) χ2 = 0.93; 0.336
CRP 1.01 (0.79–1.30) 1.07 (0.96–1.21) 1.07 (0.96–1.19) χ2 = 0.28; 0.597
a Likelihood Ratio test comparing amodel assuming outcome-specific effect for eachmodel vsmodel where the risk factor is common (i.e. constrained to be the same across outcomes).
b Small p-values indicate evidence of differences in fit between the two models, whereby the shared-effect model does not provide adequate fit for the data, and an outcome-specific
model provides a better fit.
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depressive outcomes
In bivariate probit regression analysis, we found no evidence that
ORs representing outcome-specific associations of IL-6 with psychotic
disorder and depressive episode differed from the OR representing a
common effect of IL-6 on both outcomes (p-value for likelihood ratio
test = 0.336), suggesting that IL-6 could be a common risk factor for
psychosis and depression (Table 4). Similar results were observed for
definite PEs and depressive episode (p-value for likelihood ratio test =
0.701) (Supplementary Table 7), and for CRP.
3.6. Results for sensitivity analyses using ICD-10 moderate/severe
depressive episode as outcome
Childhood IL-6 levels weremore strongly associatedwithmoderate/
severe depressive episode (adjusted OR = 1.20; 95% C.I., 1.05–1.36),
than mild depressive episode (adjusted OR = 1.12; 95% C.I.,
0.86–1.46) (p-value for likelihood ratio test = 0.014). There was no ev-
idence for an association of CRPwith eithermild ormoderate/severe de-
pression (Supplementary Table 8).
3.7. Results for sensitivity analyses using multiple imputation for
missing data
Results were largely similar to primary analyses. Evidence of associ-
ations remained for continuous IL-6 levels at age 9with psychotic disor-
der (adjusted OR = 1.41; 95% C.I., 1.12–2.25) and negative symptoms
(adjusted β = 0.04; 95% C.I., 0.00–0.07) at age 24. Similarly, following
imputation, participants in the top, compared with bottom, third of IL-
6 at age 9 had higher risk of psychotic disorder (adjusted OR = 1.54;
95% C.I., 1.02–2.11) and higher negative symptoms (adjusted β =
0.14; 95% C.I., 0.00–0.29). However, the association of continuous IL-6
levels with depressive episode attenuated slightly (adjusted OR for con-
tinuous IL-6 levels = 1.08; 95% C.I., 0.98–1.21), (OR for top, compared
with bottom third of IL-6 = 1.19; 95% C.I., 0.98–1.44). As in the primary
analysis, therewas no evidence for associations of CRPwith psychotic or
depression outcomes (Supplementary Tables 9–14).
4. Discussion
We examined associations of circulating inflammatory markers
measured in childhood with risks of psychosis and depression in adult-
hood in a large population-based prospective birth cohort. We report
that raised IL-6 levels in childhood are associated with risks for psycho-
sis and depression at age 24 in a linear dose-dependent fashion. Our re-
sults suggest that evidence for associations was stronger in more
clinically-relevant outcomes, such as psychotic disorder compared
with definite PEs, and moderate/severe depression compared with
mild depression. The results remained largely unchanged after
imputation of missing data. To our knowledge, this is one of the first
studies to report a longitudinal association between childhood
inflammation and negative symptoms in adulthood, independent of73concurrent depressive symptoms. Furthermore, having tested
outcome-specific vs common effects, we report some of the first evi-
dence for similar associations for IL-6 with psychotic and depressive
outcomes, suggesting that childhood IL-6 could be a shared risk factor
for adult psychosis and depression.
Our results are consistent with a previous study from the same
birth cohort reporting longitudinal, dose-response associations
between childhood IL-6 and risks for psychosis and depression at
age 18 years (Khandaker et al., 2014). Similar associations have
also been reported from other cohorts (Gimeno et al., 2009;
Kappelmann et al., 2019; Lamers et al., 2019; Metcalf et al., 2017;
Wium-Andersen et al., 2013; Zalli et al., 2016). The current study ex-
tends upon previous findings in a number of ways. First, we provide
evidence for potential trans-diagnostic role for inflammation, having
examined specificity vs. commonality of association between psy-
chosis and depression. Second, we included a larger number of out-
comes than in previous studies, particularly negative symptoms
which feature less-often in psychosis research. Third, using a longer
follow-up, we confirm that the effects of childhood IL-6 on risks for
psychosis and depression persist longer into adulthood, to a period
when most cases of psychiatric disorders emerge.
Our findings support that the association between inflammation and
psychiatric disorders transcends traditional diagnostic boundaries
(Khandaker et al., 2017). In addition to depression and psychosis, in-
flammation has been reported to be associated with anxiety (Rossi
et al., 2012), post-traumatic stress disorder (Eraly et al., 2014), autism
(Brown et al., 2014) and dementias (Schmidt et al., 2002). One explana-
tion for this apparent trans-diagnostic effect could be that inflammation
contributes to features common to different syndromes, such as fatigue,
anhedonia and cognitive difficulties (Khandaker et al., 2017). In addi-
tion, mental disorders show high levels of genetic overlap (Anttila
et al., 2018), and genetic correlation analysis has suggested that the ge-
netic similarity may partly arise in immune- and inflammatory-related
loci (Tylee et al., 2018).
Together with existing evidence, our findings suggest that inflam-
mation could be a common mechanism for a number of commonly co-
morbid chronic illness, such as depression, schizophrenia, coronary
heart disease and diabetes mellitus (Khandaker et al., 2020). These ill-
nesses are associated with inflammation (Danesh et al., 2008;
Goldsmith et al., 2016; Pradhan et al., 2001), which could be linked
with early-life factors influencing inflammatory regulation, such as im-
paired foetal development or childhood maltreatment. This idea is con-
sistent with the common-cause or developmental programming
hypothesis by David Barker, which posits that exposure to adversity
during a critical ‘developmental window’ might permanently alter cer-
tain physiologic system(s) leading to increased risk of chronic illnesses
in adult life (Barker, 1993). Indeed, childhood adversity, a known risk
factor for depression, schizophrenia and cardiovascular disease, is
linked with increased levels of circulating inflammatory markers in
adulthood (Baumeister et al., 2016).
Althoughwe adjusted for sex, ethnicity, social class and BMI, as with
all observational research, residual confounding still might explain the
associations of IL-6 with depression and psychosis. Evidence from
Mendelian randomization (MR) studies, which use genetic variants
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of confounding, suggest that IL-6 and CRP could be potentially causally
related to depression and psychosis (Hartwig et al., 2017; Khandaker
et al., 2018c; Khandaker et al., 2020). This suggests that our results are
unlikely to be explained fully by confounding. Furthermore, meta-
analyses of secondary data from randomized controlled trials (RCTs)
suggest that anti-cytokine drugs, including anti-IL-6 drugs, improve de-
pressive symptoms in patients with chronic inflammatory disease inde-
pendently of improving physical illness (Kappelmann et al., 2018;
Wittenberg et al., 2020). Our findings, together with existing evidence,
support therapeutic targeting of the immune system in depression
and psychosis.
Inflammation is clinically relevant as elevated inflammatory
markers are associated with poor response to antidepressants and anti-
psychotics in patients with depression and psychosis, respectively
(Carvalho et al., 2013; Mondelli et al., 2015). However, inflammation
is likely to be relevant for some, not all, cases of depression or psychosis,
as meta-analyses have reported that evidence of inflammation,
e.g., elevated CRP levels (>3mg/L), are present in about a quarter of pa-
tients with depression (Osimo et al., 2019) or psychosis (Miller et al.,
2014). Therefore, immunological studies may provide an opportunity
for future personalized medicine approaches to understanding patho-
physiologic mechanisms, and uncovering potential new treatment op-
tions for these disorders.
While immunotherapies could have a role in depression or psycho-
sis, identifying patientsmost likely to benefit is key for the success of fu-
ture randomized controlled trials (RCTs) in this field. An RCT of
depression suggests that immunotherapies may be more suitable for
patients with evidence of inflammation (Raison et al., 2013). A recent
RCT reported no favourable effect of tocilizumab, an anti-IL-6 receptor
monoclonal antibody, in patients with established schizophrenia
(Girgis et al., 2018), whichmay be related to patient selection regardless
of evidence of immune-activation. Indeed, a number of ongoing RCTs
are now selecting patients based on evidence of inflammation,
e.g., elevated CRP levels and/or inflammation-related symptoms
(Khandaker et al., 2018b). In future, further RCTs of immunotherapies
including anti-IL-6 treatment for depression and psychosis with careful
patient selection criteria are required.
One potential explanation for the null findings for CRP could bemea-
surement error. CRP may be susceptible to diurnal variation (Rudnicka
et al., 2007), increasing the chance of measurement error that is likely
to be random in relationship with the outcome. Randommeasurement
error in relation to the outcomemay increase the likelihood of null find-
ings. In addition, although observational studies have consistently re-
ported elevated CRP and IL-6 levels in depression and schizophrenia
(Goldsmith et al., 2016; Haapakoski et al., 2015; Miller et al., 2011;
Upthegrove et al., 2014), MR analysis has reported a protective effect
of CRP for schizophrenia (Hartwig et al., 2017). This is puzzling since
IL-6 stimulates the production of CRP. However, it is possible that ge-
netic predisposition for decreased CRP levels/activity increase suscepti-
bility to infection leading to increased schizophrenia risk through
immune, neurodevelopmental and/or other mechanisms (Hartwig
et al., 2017; Khandaker et al., 2018a). In future, genomic methods
which are able to consider the effect of multiple inflammatory markers
together, such as multivariable MR, may be helpful to examine the ef-
fects of genetically predicted levels of CRP taking into account that for
IL-6.
Strengths of this work include the longitudinal design, the use of
prospectively collected data from a large general population-based
birth cohort, and the inclusion of a larger number of outcomes for psy-
chosis and depression than previous studies.We adjusted for important
potential confounders including sex, ethnicity, social class and BMI. We
further examined the nature of associations using tests for linearity, for
example comparing ORs for binary psychiatric outcomes over thirds of
inflammatory marker distribution and including quadratic terms in re-
gression models. The use of bivariate probit analysis permitted testing74for specificity of association between childhood inflammatory markers
and psychiatric outcomes in adulthood.
Limitations of the study include missing data, a common issue for
prospective cohort studies. However, we assessed robustness of our
findings using sensitivity analyses including multiple imputation for
missing data, and the findings were largely unchanged. This suggests
that missing data was unlikely to have significantly impacted our find-
ings. Secondly, the dataset we used did not have ICD/DSM diagnosis of
schizophrenia available, although our psychotic disorder outcome
would likely meet a clinical threshold for the consideration of treat-
ment.While our psychosis outcomes lie along the continuumof psycho-
sis, PEs do not exclusively represent psychosis-risk, and have previously
been reported to be associated with other mental disorders including
anxiety and depression (Varghese et al., 2011). The significance of neg-
ative symptoms in the general population in the absence of schizophre-
nia remains unclear (Werbeloff et al., 2015). Also regarding negative
symptoms, the outcome measure was derived from a self-report ques-
tionnaire, rather than assessment by trained researchers/clinicians.
This may have affected the accuracy of our measure for negative symp-
toms. Additionally, we included childhood inflammatory markers mea-
sured at a single time-point, so it is unclear to what extent they reflect
persistent inflammation. However, it has been reported that IL-6 levels
remain relatively stable over at least a three-year period (Knudsen et al.,
2008). Future longitudinal studies should seek to include repeat mea-
sures of childhood IL-6 to examine effects of persistent inflammation,
elevated IL-6 particularly, on the risk of adult mental disorders. Finally,
we were only able to include two inflammatory markers in our study,
since ALSPAC only collected data on CRP and IL-6. Future studies should
also include a wider range of inflammatory markers, to foster a broader
understanding of network-level changes, possibly involving wider in-
flammatory pathways.
In conclusion, we report evidence for longitudinal, dose-response
associations of childhood IL-6 levelswith risks for psychosis and depres-
sion in adulthood,with the strongest associations formore clinically rel-
evant outcomes. Furthermore, we provide empirical evidence that IL-6
could be a shared risk factor for these disorders. Our findings suggest
that the IL-6 pathway could represent a putative novel target for treat-
ment/ prevention of psychosis and depression.Financial support
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